Lilly's Cyramza misses OS endpoint in Phase III for urothelial carcinoma

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RANGE trial in 530 patients with urothelial carcinoma showing that IV Cyramza ramucirumab plus docetaxel missed the secondary endpoint of improving overall survival (OS) vs. placebo plus docetaxel. Last year, Lilly said Cyramza plus docetaxel met the trial’s primary endpoint of improving progression-free survival (PFS) vs. placebo plus docetaxel (see BioCentury, Aug. 28, 2017).

Lilly said it will review the data with internal and external experts to determine next steps. The double-blind, international trial enrolled patients with locally advanced, unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based chemotherapy...